Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

6.77
-0.3000-4.24%
Volume:61.63K
Turnover:436.99K
Market Cap:258.58M
PE:-2.04
High:7.33
Open:7.24
Low:6.74
Close:7.07
Loading ...

Iteos Therapeutics Inc Q4 Shr View $-1.06 -- Lseg Ibes Data

THOMSON REUTERS
·
05 Mar

Press Release: iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
05 Mar

iTeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Jan

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

Zacks
·
14 Jan

iTeos Therapeutics Plans 2025 Data Presentation on Therapies

TIPRANKS
·
13 Jan

Iteos Therapeutics Inc - Eos-984 Phase 1 Monotherapy and Pd-1 Combination Data Expected in 2H25

THOMSON REUTERS
·
10 Jan

Iteos Therapeutics Inc - Cash Balance of $683.9 Million Expected to Provide Runway Through 2027

THOMSON REUTERS
·
10 Jan

Iteos Therapeutics Inc - Eos-215 Ind Submission Anticipated in 1Q25

THOMSON REUTERS
·
10 Jan

Iteos Announces 2025 Strategic Priorities and Anticipated Milestones

THOMSON REUTERS
·
10 Jan

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

GlobeNewswire
·
10 Jan

iTeos Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
19 Dec 2024

iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo

TIPRANKS
·
19 Dec 2024

iTeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Dec 2024

Iteos Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $21 From $46

THOMSON REUTERS
·
13 Dec 2024

Iteos Therapeutics Inc : Piper Sandler Cuts Target Price to $16 From $36

THOMSON REUTERS
·
13 Dec 2024

iTeos Therapeutics Says Deprioritizing Cancer Drug Candidate Inupadenant

MT Newswires Live
·
12 Dec 2024

iTeos Therapeutics presents interim A2A-005 clinical trial data

TIPRANKS
·
12 Dec 2024

Iteos Therapeutics Presents Interim a2a-005 Clinical Trial Data, Translational, and Preclinical Data From Inupadenant at Esmo Immuno-Oncology Congress

THOMSON REUTERS
·
12 Dec 2024

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

GlobeNewswire
·
12 Dec 2024

iTeos to Participate in Upcoming Investor Conferences

GlobeNewswire
·
26 Nov 2024